Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
The present disclosure relates to the genetically modified non-human animals that express a human or chimeric CTLA-4, and methods of use thereof.
1. A method of evaluating an anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody for the treatment of cancer, the method comprising:
a) administering an anti-CTLA-4 antibody to a genetically modified mouse that has a tumor, and
b) determining whether the antibody inhibits the tumor,
wherein the genetically modified mouse has a genome comprising a nucleic acid sequence encoding a chimeric CTLA-4 comprising an amino acid sequence that is at least 95% identical to the, amino acid sequence of SEQ ID NO: 41, wherein the nucleic acid sequence: i) comprises exons 1, 3, 4, of a mouse CTLA-4 gene and a humanized exon 2 of the CTLA-4 gene, and ii) is operably linked to an endogenous promoter of the mouse CTLA-4 gene, and wherein the mouse functionally expresses the chimeric CTLA-4.
2. The method of claim 1 , wherein the chimeric CTLA-4 comprises the amino acid sequence of SEQ ID NO: 41.
3. The method of claim 1 , wherein the mouse does not express endogenous CTLA-4.
4. The method of claim 1 , wherein the mouse is homozygous with respect to the nucleic acid sequence encoding the chimeric CTLA-4.
5. The method of claim 1 , wherein the mouse further comprises a nucleic acid sequence encoding an additional human or humanized protein.
6. The method of claim 5 , wherein the additional human or humanized protein is programmed cell death protein 1 (PD-1), TNF Receptor Superfamily Member 4 (OX40), Lymphocyte Activating 3 (LAG-3), Programmed Cell Death 1 Ligand 1 (PD-L1), CD47, or T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT).
7. The method of claim 1 , wherein the tumor comprises human cancer cells.
8. The method of claim 1 , wherein the anti-CTLA-4 antibody is an anti-human CTLA-4 antibody.
9. A method of evaluating an anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody for the treatment of cancer, the method comprising:
a) administering an anti-CTLA-4 antibody to a genetically modified mouse that has a tumor, and
b) determining whether the antibody inhibits the tumor,
wherein the genetically modified mouse has a genome comprising exon 1, exon 3, and exon 4 of an endogenous CTLA-4 gene and a modification of endogenous exon 2 comprising a replacement of 50-330 nucleotides of endogenous exon 2 with 50-330 nucleotides from exon 2 of a human CTLA-4 gene, wherein the mouse functionally expresses a chimeric CTLA-4 protein.
10. The method of claim 9 , wherein the tumor comprises human cancer cells.
11. The method of claim 9 , wherein the anti-CTLA-4 antibody is an anti-human CTLA-4 antibody.
12. The method of claim 9 , wherein the mouse further comprises a nucleic acid sequence encoding an additional human or humanized protein.
13. The method of claim 12 , wherein the additional human or humanized protein is programmed cell death protein 1 (PD-1), TNF Receptor Superfamily Member 4 (OX40), Lymphocyte Activating 3 (LAG-3), Programmed Cell Death 1 Ligand 1 (PD-L1), CD47 or T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT).